Alopecia
Recent clinical, regulatory, research and industry developments relating to this disease.
The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q2 2027.
- 3 industry developments reported.
- Q2 2027A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia
- Q4 2027Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.
- Q1 2028A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- Q1 2029A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss
- Q2 2030A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
Clinical MilestonesView all 11Hide
- 2026-04-16A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia AreataResults posted
- 2026-04-09A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATAResults posted
- 2026-08-17A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic AlopeciaResults expected Q2 2027
- 2026-07-30A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair LossResults expected Q1 2029
- 2026-07-06A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia AreataResults expected Q2 2030
- 2026-05-20A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataResults expected Q1 2028
- 2026-04-28A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031Results expected Q2 2030
- 2026-05-15Phase 3, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Minoxidil Sublingual (SL) Tablet (2.5 mg) Twice Daily (BID) in the Treatment of Male Androgenetic Alopecia (AGA) in AdultsCompleted
- 2026-01-26A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle SolutionCompleted
Industry & MarketViewHide
- 2026-07-13Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitorsTrial news · Fierce Biotech
- 2026-09-17Sun Pharma shines a light on alopecia areata in ‘Regrowth Restyled’ campaignIndustry · Fierce Pharma
- 2026-09-11Alopecia Areata Consensus Statement Recommends First-Line RxIndustry · Medscape Medical News
- 2026-09-17IndustrySun Pharma shines a light on alopecia areata in ‘Regrowth Restyled’ campaignIndustry · Fierce Pharma
- 2026-09-11IndustryAlopecia Areata Consensus Statement Recommends First-Line RxIndustry · Medscape Medical News
- 2026-08-17ClinicalA Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic AlopeciaResults expected Q2 2027
- 2026-07-30ClinicalA Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair LossResults expected Q1 2029
- 2026-07-13IndustryQ32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitorsTrial news · Fierce Biotech
- 2026-07-06ClinicalA Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia AreataResults expected Q2 2030
- 2026-05-21ClinicalA Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia AreataTerminated
- 2026-05-20ClinicalA Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataResults expected Q1 2028
- 2026-05-15ClinicalPhase 3, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Minoxidil Sublingual (SL) Tablet (2.5 mg) Twice Daily (BID) in the Treatment of Male Androgenetic Alopecia (AGA) in AdultsCompleted
- 2026-04-28ClinicalA LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031Results expected Q2 2030
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe ac… (2017)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Alopecia3
- Hair Follicle2
- Cosmetic Techniques1
- Esthetics1
- Interferon-gamma1
- Stem Cell Transplantation1
- T-Lymphocytes, Regulatory1
- Transgender Persons1
Leading journals6
- Advanced materials (Deerfield Beach, Fla.)1
- Blood1
- Cells1
- International journal of molecular sciences1
- Journal of the American Academy of Dermatology1
- Medicine1
Leading researchers8
- Al-Tameemi W1
- Artzi N1
- Azzi JR1
- Badaoui A1
- Bajo Gauzin D1
- Bonati LM1
- Burke JM1
- Cardenas-Lopez A1
Affiliations (unnormalised)6
- American University of Beirut1
- Brigham and Woman's Hospital1
- Brigham and Women's Hospital1
- Center for Infectious Medicine1
- Center for Neuroregeneration1
- Emory University School of Medicine1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Alopecia is the absence of hair from areas where hair is normally present. The supplied grounding also indicates that hair loss can be discussed in specific forms such as androgenetic alopecia and chemotherapy-induced alopecia, but the core definition is simply loss of hair.
The grounding supports a genetic contribution for androgenetic alopecia, and it also identifies chemotherapy as a cause of chemotherapy-induced alopecia. Beyond these examples, no broader aetiology is supported in the supplied material.
The supplied reviews point to hair follicle biology and follicle cycling as central to hair loss, with androgenetic alopecia involving molecular and transcriptional differences between balding and non-balding scalp regions. For chemotherapy-induced alopecia, anticancer agents damage the hair follicle and alter subsequent follicle pathophysiology. Stem-cell and Wnt/growth-factor signaling are discussed as mechanisms relevant to hair regrowth and follicle development, but not as established disease mechanisms for all alopecia.
For androgenetic alopecia, genetics and aging are supported risk factors, and lifestyle is also mentioned as a contributing factor. No other general risk factors are supported by the supplied grounding.
For chemotherapy-induced alopecia, scalp cooling is described as the only safe U.S. FDA-cleared prevention modality in the supplied review. The other grounded literature discusses regenerative and stem-cell-based approaches, platelet-rich plasma, and growth-factor or Wnt-pathway-related strategies for hair regrowth, but these are presented as investigational or emerging rather than established standard care.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Absence of hair from areas where it is normally present.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.